Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Atherosclerosis. 2014 Nov 20;238(1):77–82. doi: 10.1016/j.atherosclerosis.2014.11.012

Figure 2.

Figure 2

The crude prevalence of musculoskeletal pain according to serum 25(0H)D (ng/mL) concentration and statin use among 2001-2004 NHANES. Among statins users, 43.8% (n=72) who had 25(0H)D<15 ng/mL, 29.2% (n=162) who had 25(0H)D between 15-30 ng/m L, and 24.5% (n=41) who had 25(0H)D 30 ng/m L, reported experiencing musculoskeletal pain in the past month. Among those not using statins, 26.6% (n=255) who had 25(0H)D<15 ng/mL, 27.3% (n=704) who had 25(0H)D between15-30 ng/mL, and 23.7% (n=195) who had 25(0H)D 30 ng/mL, reported experiencing musculoskeletal pain in the past month.